ClinicalTrials.gg
CompletedNCT01375764GAUSSUpdated Nov 7, 2022Results posted

Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin Intolerant Subjects

A Phase 2 interventional study of Evolocumab and Ezetimibe in Hyperlipidemia, sponsored by Amgen. Completed at 42 sites in 8 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-11-07.

Sponsored by Amgen · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 21 studies testing evolocumab in Hyperlipidemias — none open to participants now, none under way, none of them phase 3. evolocumab · Hyperlipidemias.

Enrollment
12th of 21
160 · median 307
Started
2011
with 2 others
Phase 2
3 of 21
none open now
Registered
2nd of 21
by date
Lead sponsor
16 of 21
Amgen

Among the 21 studies testing evolocumab in Hyperlipidemias, this one is the 12th largest by enrollment, is one of 3 that started in 2011, is one of 3 in phase 2, and was the 2nd registered.

Hyperlipidemias

862 studies on the registry are indexed under Hyperlipidemias; 109 are open to participants now.

Browse Hyperlipidemias studies →

Open to participants now

None of the 21 studies testing evolocumab in Hyperlipidemias is open now. The open studies under Hyperlipidemias, anywhere →

About evolocumab

evolocumab: first FDA approval 2015 (REPATHA), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 67 Hyperlipidemias studies recruiting now, 27 (40%) set no upper age limit and 32 (48%) stop at 75 or younger; 8 take children under 18; 16 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 21 studies testing evolocumab in Hyperlipidemias as a file.
02

Study summary

The primary objective was to evaluate the effect of 12 weeks of subcutaneous evolocumab (AMG 145), compared with ezetimibe, on percent change from baseline in low-density lipoprotein cholesterol (LDL-C) in patients with hypercholesterolemia unable to tolerate an effective dose of a statin.

03

Conditions studied

  • Hyperlipidemia

Keywords

  • Proprotein convertase subtilisin/kexin type 9 (PCSK9)
  • Cholesterol
  • High Cholesterol
  • Raised Cholesterol
  • Elevated Cholesterol
  • Statin intolerant
  • Hypercholesterolemia
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female ≥ 18 to ≤ 75 years of age
  • On a statin or a low dose statin with stable dose for at least 4 weeks
  • Lipid lowering therapy has been stable prior to enrollment
  • Fasting triglycerides must be \< 400 mg/dL.
  • Subject not at LDL-C goal

Exclusion criteria

Exclusion Criteria:

  • (NYHA) III or IV heart failure or known \< 30%
  • Uncontrolled cardiac arrhythmia
  • Myocardial infarction, unstable angina, percutaneous coronary intervention (PCI), coronary artery bypass graft (CABG) or stroke within 3 months prior to randomization
  • Type 1 diabetes or newly diagnosed type 2 diabetes ( > 8.5%)
  • Uncontrolled hypertension
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
160 participants (actual)

Study arms

  • Active comparator
    Ezetimibe

    Participants received placebo subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.

    Drug: Ezetimibe · Other: Placebo to Evolocumab

  • Experimental
    Evolocumab + Ezetimibe

    Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks and 10 mg ezetimibe orally once a day for 12 weeks.

    Biological: Evolocumab · Drug: Ezetimibe

  • Experimental
    Evolocumab 280 mg

    Participants received 280 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 350 mg

    Participants received 350 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

  • Experimental
    Evolocumab 420 mg

    Participants received 420 mg evolocumab by subcutaneous injection once every 4 weeks for 12 weeks.

    Biological: Evolocumab

Interventions

  • BiologicalEvolocumab

    Administered by subcutaneous injection

    Also known as: AMG 145, Repatha

  • Administered orally once a day

    Also known as: Zetia

  • OtherPlacebo to Evolocumab

    Administered by subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

    LDL-C was measured using ultracentrifugation. Least squares (LS) means are based off an analysis of covariance (ANCOVA) model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

    Time frame: Baseline and Week 12

  2. Percent Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

    LDL-C was measured using ultracentrifugation. LS means are based off an ANCOVA model which includes treatment group (evolocumab + ezetimibe and ezetimibe alone) and stratification factors as covariates.

    Time frame: Baseline and Week 12

Secondary outcomes

  1. Change From Baseline in LDL-C at Week 12

    LDL-C was measured using ultracentrifugation. LS means are based off an ANCOVA model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

    Time frame: Baseline and Week 12

  2. Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

    LDL-C was measured using ultracentrifugation. LS means are based off an ANCOVA model which includes treatment group (evoloumab + ezetimibe and ezetimibe alone) and stratification factors as covariates.

    Time frame: Baseline and Week 12

  3. Percent Change From Baseline in Non-HDL-C at Week 12

    LS means are based off an ANCOVA model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

    Time frame: Baseline and Week 12

  4. Percent Change From Baseline in Non-HDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

    LS means are based off an ANCOVA model which includes treatment group (evolocumab + ezetimibe and ezetimibe alone) and stratification factors as covariates.

    Time frame: Baseline and Week 12

  5. Percent Change From Baseline in Apolipoprotein B at Week 12

    LS means are based off an ANCOVA model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

    Time frame: Baseline and Week 12

  6. Percent Change From Baseline in Apolipoprotein B at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

    LS means are based off an ANCOVA model which includes treatment group (evoloumab + ezetimibe and ezetimibe) and stratification factors as covariates.

    Time frame: Baseline and Week 12

  7. Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12

    LS means are based off an ANCOVA model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

    Time frame: Baseline and Week 12

  8. Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

    LS means are based off an ANCOVA model which includes treatment group (evoloumab + ezetimibe and ezetimibe alone) and stratification factors as covariates.

    Time frame: Baseline and Week 12

  9. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12

    LS means are based off an ANCOVA model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

    Time frame: Baseline and Week 12

  10. Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

    LS means are based off an ANCOVA model which includes treatment group (evoloumab + ezetimibe and ezetimibe alone) and stratification factors as covariates.

    Time frame: Baseline and Week 12

07

Results

Posted Dec 23, 2015

Participant flow

The study enrolled adults aged 18 to 75 years with hypercholesterolemia who were statin intolerant and with low-density lipoprotein cholesterol (LDL-C) levels above risk-based goals recommended by the National Cholesterol Education Program. The first patient enrolled on 28 July 2011; last patient enrolled 14 February 2012.

Participant flow — Overall Study
MilestoneEzetimibeEvolocumab + EzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mg
Started3331323232
Received treatment3230323132
Completed3130323131
Not completed21011
Withdrew: Lost to follow-up01000
Withdrew: Withdrawal by subject20001
Withdrew: Other00010

Outcome measures

PrimaryPercent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12

LDL-C was measured using ultracentrifugation. Least squares (LS) means are based off an analysis of covariance (ANCOVA) model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12
percent changeEzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mg
Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) at Week 12-14.76 ± 3.94-40.77 ± 3.96-42.58 ± 4.01-50.70 ± 3.98
Statistical analysis
  • Ezetimibe vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -35.94 · 95% CI -44.08 to -27.80Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean treatment difference: -27.82 · 95% CI -35.97 to -19.67Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 280 mg · ANCOVA · p = <0.001 (Multiplicity adjusted p-value is significant if less than the familywise error rate of 0.05.) · Ls mean tretament difference: -26.01 · 95% CI -34.08 to -17.93Ezetimibe is the reference.
PrimaryPercent Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

LDL-C was measured using ultracentrifugation. LS means are based off an ANCOVA model which includes treatment group (evolocumab + ezetimibe and ezetimibe alone) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
percent changeEzetimibeEvolocumab + Ezetimibe
Percent Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe-15.70 ± 3.98-62.98 ± 4.22
Statistical analysis
  • Ezetimibe vs Evolocumab + Ezetimibe · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -47.29 · 95% CI -53.73 to -40.84Ezetimibe is the reference.
SecondaryChange From Baseline in LDL-C at Week 12

LDL-C was measured using ultracentrifugation. LS means are based off an ANCOVA model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 12
mg/dLEzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mg
Change From Baseline in LDL-C at Week 12-14.2 ± 8.9-66.8 ± 8.9-69.7 ± 9.1-90.8 ± 9.0
Statistical analysis
  • Ezetimibe vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -76.6 · 95% CI -94.9 to -58.3Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -55.5 · 95% CI -74.0 to -37.1Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 280 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -52.6 · 95% CI -70.8 to -34.5Ezetimibe is the reference.
SecondaryChange From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

LDL-C was measured using ultracentrifugation. LS means are based off an ANCOVA model which includes treatment group (evoloumab + ezetimibe and ezetimibe alone) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · mg/dL
Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
mg/dLEzetimibeEvolocumab + Ezetimibe
Change From Baseline in LDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe-17.9 ± 10.4-109.8 ± 11.0
Statistical analysis
  • Ezetimibe vs Evolocumab + Ezetimibe · ANCOVA · p = <0001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -91.9 · 95% CI -108.7 to -75.0Ezetimibe is the reference.
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12

LS means are based off an ANCOVA model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12
percent changeEzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mg
Percent Change From Baseline in Non-HDL-C at Week 12-14.97 ± 3.54-39.83 ± 3.56-41.63 ± 3.61-48.58 ± 3.58
Statistical analysis
  • Ezetimibe vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -33.60 · 95% CI -40.93 to -26.28Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -26.66 · 95% CI -33.99 to -19.32Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 280 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -24.86 · 95% CI -32.13 to -17.59Ezetimibe is the reference.
SecondaryPercent Change From Baseline in Non-HDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

LS means are based off an ANCOVA model which includes treatment group (evolocumab + ezetimibe and ezetimibe alone) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Non-HDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
percent changeEzetimibeEvolocumab + Ezetimibe
Percent Change From Baseline in Non-HDL-C at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe-14.83 ± 3.59-59.82 ± 3.81
Statistical analysis
  • Ezetimibe vs Evolocumab + Ezetimibe · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -45.00 · 95% CI -50.81 to -39.18Ezetimibe is the reference.
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 12

LS means are based off an ANCOVA model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at Week 12
percent changeEzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mg
Percent Change From Baseline in Apolipoprotein B at Week 12-12.20 ± 3.37-33.58 ± 3.39-34.33 ± 3.43-42.07 ± 3.40
Statistical analysis
  • Ezetimibe vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05) · Ls mean teatment difference: -29.88 · 95% CI -36.84 to -22.92Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -22.13 · 95% CI -29.10 to -15.16Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 280 mg · ANCOVA · p = <0.001 (Testing based on a signficance level of 0.05.) · Ls mean treatment difference: -21.38 · 95% CI -28.29 to -14.48Ezetimibe is the reference.
SecondaryPercent Change From Baseline in Apolipoprotein B at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

LS means are based off an ANCOVA model which includes treatment group (evoloumab + ezetimibe and ezetimibe) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
percent changeEzetimibeEvolocumab + Ezetimibe
Percent Change From Baseline in Apolipoprotein B at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe-10.84 ± 3.45-49.06 ± 3.66
Statistical analysis
  • Ezetimibe vs Evolocumab + Ezetimibe · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05) · Ls mean treatment difference: -38.23 · 95% CI -43.81 to -32.64Ezetimibe is the reference.
SecondaryPercent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12

LS means are based off an ANCOVA model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12
percent changeEzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mg
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12-9.61 ± 3.20-31.97 ± 3.22-33.52 ± 3.26-40.56 ± 3.23
Statistical analysis
  • Ezetimibe vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -30.95 · 95% CI -37.56 to -24.34Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -23.91 · 95% CI -30.53 to -17.29Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 280 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -22.36 · 95% CI -28.92 to -15.80Ezetimibe is the reference.
SecondaryPercent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

LS means are based off an ANCOVA model which includes treatment group (evoloumab + ezetimibe and ezetimibe alone) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
percent changeEzetimibeEvolocumab + Ezetimibe
Percent Change From Baseline in Total Cholesterol/HDL-C Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe-11.52 ± 3.61-49.44 ± 3.83
Statistical analysis
  • Ezetimibe vs Evolocumab + Ezetimibe · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -37.92 · 95% CI -43.77 to -32.07Ezetimibe is the reference.
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12

LS means are based off an ANCOVA model which includes treatment group (3 evolocumab alone dose groups and the ezetimibe group) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12
percent changeEzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mg
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12-11.36 ± 3.16-36.46 ± 3.18-38.17 ± 3.22-45.41 ± 3.19
Statistical analysis
  • Ezetimibe vs Evolocumab 420 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -34.05 · 95% CI -40.57 to -27.52Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 350 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -26.81 · 95% CI -33.35 to -20.27Ezetimibe is the reference.
  • Ezetimibe vs Evolocumab 280 mg · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -25.10 · 95% CI -31.57 to -18.62Ezetimibe is the reference.
SecondaryPercent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe

LS means are based off an ANCOVA model which includes treatment group (evoloumab + ezetimibe and ezetimibe alone) and stratification factors as covariates.

Time frame:
Baseline and Week 12
Reported as:
Least squares mean · percent change
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe
percent changeEzetimibeEvolocumab + Ezetimibe
Percent Change From Baseline in Apolipoprotein B/Apolipoprotein A1 Ratio at Week 12: Ezetimibe Alone Versus Evolocumab + Ezetimibe-10.74 ± 3.55-51.99 ± 3.76
Statistical analysis
  • Ezetimibe vs Evolocumab + Ezetimibe · ANCOVA · p = <0.001 (Testing based on a significance level of 0.05.) · Ls mean treatment difference: -41.25 · 95% CI -46.99 to -35.50Ezetimibe is the reference.

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ezetimibe—0/32 (0%)16/32 (50%)
Evolocumab 280 mg—2/32 (6.3%)19/32 (59.4%)
Evolocumab 350 mg—1/31 (3.2%)10/31 (32.3%)
Evolocumab 420 mg—1/32 (3.1%)12/32 (37.5%)
Evolocumab + Ezetimibe—0/30 (0%)18/30 (60%)
Most frequent serious events
Most frequent serious events
EventEzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mgEvolocumab + Ezetimibe
SyncopeNervous system disorders0/320/321/310/320/30
Coronary artery diseaseCardiac disorders0/320/320/311/320/30
Pancreatitis acuteGastrointestinal disorders0/321/320/310/320/30
Femoral neck fractureInjury, poisoning and procedural complications0/321/320/310/320/30
Most frequent other events
Showing 10 of 22
Most frequent other events
EventEzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mgEvolocumab + Ezetimibe
MyalgiaMusculoskeletal and connective tissue disorders1/325/321/311/326/30
HeadacheNervous system disorders0/320/321/310/326/30
NasopharyngitisInfections and infestations5/322/322/311/323/30
FatigueGeneral disorders2/324/320/310/320/30
ConstipationGastrointestinal disorders0/320/321/311/323/30
Upper respiratory tract infectionInfections and infestations0/320/321/311/323/30
Pain in extremityMusculoskeletal and connective tissue disorders1/320/320/312/323/30
Muscle spasmsMusculoskeletal and connective tissue disorders3/321/322/310/320/30
Oropharyngeal painRespiratory, thoracic and mediastinal disorders0/320/320/313/320/30
CystitisInfections and infestations0/321/320/310/322/30

Baseline characteristics

Full analysis set (all randomized participants who received at least 1 dose of investigational product).

Age, Continuous
Age, Continuous(years)EzetimibeEvolocumab + EzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mgTotal
Mean62.4 ± 6.662.0 ± 7.262.2 ± 10.162.3 ± 9.160.0 ± 8.661.8 ± 8.4
Sex: Female, Male
Sex: Female, Male(Participants)EzetimibeEvolocumab + EzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mgTotal
Female1823182120100
Male14714101257
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)EzetimibeEvolocumab + EzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mgTotal
American Indian or Alaska Native000000
Asian251008
Black or African American212218
Native Hawaiian or Other Pacific Islander000011
White2824282930139
Other001001
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)EzetimibeEvolocumab + EzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mgTotal
Hispanic or Latino200002
Not Hispanic or Latino3030323132155
Stratification Factor: LDL-C Level
Stratification Factor: LDL-C Level(participants)EzetimibeEvolocumab + EzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mgTotal
< 130 mg/dL212229
≥ 130 mg/dL3029302930148
Stratification Factor: Baseline Use of Statin
Stratification Factor: Baseline Use of Statin(participants)EzetimibeEvolocumab + EzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mgTotal
No2626272727133
Yes6454524
LDL-C Concentration
LDL-C Concentration(mg/dL)EzetimibeEvolocumab + EzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mgTotal
Mean182.9 ± 36.4194.4 ± 60.1194.8 ± 48.1190.3 ± 47.8203.5 ± 60.3193.2 ± 51.0
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration
Non-High-Density Lipoprotein Cholesterol (non-HDL-C) Concentration(mg/dL)EzetimibeEvolocumab + EzetimibeEvolocumab 280 mgEvolocumab 350 mgEvolocumab 420 mgTotal
Mean213.7 ± 40.4219.8 ± 60.5225.5 ± 53.3222.9 ± 55.8240.6 ± 63.9224.6 ± 55.3

3 further baseline measures are reported on the registry.

08

Study locations

42 sites
  • Research Site
    Anaheim, California 92801, United States
  • Research Site
    Mission Viejo, California 92691, United States
  • Research Site
    Westlake Village, California 91361, United States
  • Research Site
    Atlanta, Georgia 30338, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Savannah, Georgia 31406, United States
  • Research Site
    Auburn, Maine 04210, United States
  • Research Site
    Chevy Chase, Maryland 20815, United States
  • Research Site
    Butte, Montana 59701, United States
  • Research Site
    Henderson, Nevada 89052, United States
  • Research Site
    Las Vegas, Nevada 89117, United States
  • Research Site
    New York, New York 10029, United States
  • Research Site
    Raleigh, North Carolina 27609, United States
  • Research Site
    Akron, Ohio 44311, United States
  • Research Site
    Cincinnati, Ohio 45212, United States
  • Research Site
    Bristol, Tennessee 37620, United States
  • Research Site
    Camperdown, New South Wales 2015, Australia
  • Research Site
    Sydney, New South Wales 2022, Australia
  • Research Site
    Melbourne, Victoria 3004, Australia
  • Research Site
    Perth, Western Australia 6000, Australia
  • Research Site
    Bruxelles, 1200, Belgium
  • Research Site
    Uccle, 1180, Belgium
  • Research Site
    Saint John’s, Newfoundland and Labrador A1A 3R5, Canada
  • Research Site
    St. John's, Newfoundland and Labrador A1A 3R5, Canada
  • Research Site
    Lachine, Quebec H8S 2E4, Canada
  • Research Site
    Ballerup, 2750, Denmark
  • Research Site
    Vejle, 7100, Denmark
  • Research Site
    Helsinki, 00029, Finland
  • Research Site
    OYS, 90029, Finland
  • Research Site
    Zaragoza, Aragón 50009, Spain
  • Research Site
    Zaragoza, Aragón 50009, Spain
  • Research Site
    Barcelona, Cataluña 08036, Spain
  • Research Site
    L'Hospitalet de Llobregat, Cataluña 08907, Spain
  • Research Site
    Reus, Cataluña 43204, Spain
  • Research Site
    Barcelona, Cataluña 08036, Spain
  • Research Site
    L'Hospitalet de Llobregat, Cataluña 08907, Spain
  • Research Site
    Reus, Cataluña 43204, Spain
  • Research Site
    Göteborg, 411 36, Sweden
  • Research Site
    Göteborg, 411 36, Sweden
  • Research Site
    Lund, 222 21, Sweden
  • Research Site
    Stockholm, 111 35, Sweden
  • Research Site
    Stockholm, 141 86, Sweden
09

References and documents

Publications

  • Sullivan D, Olsson AG, Scott R, Kim JB, Xue A, Gebski V, Wasserman SM, Stein EA. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial. JAMA. 2012 Dec 19;308(23):2497-506. doi: 10.1001/jama.2012.25790. PubMed 23128163 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jul 2011 to primary completion in May 2012, 9 months.

Results were first posted in Dec 2015, 3 years 7 months after primary completion. A results delay was requested in Mar 2013.

Of 30 phase 2 interventional studies under Hyperlipidemias, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's 9 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 16, 2011
First posted
Jun 17, 2011
StartActual
Jul 28, 2011
Primary completionActual
May 8, 2012
CompletionActual
May 8, 2012
Results delay requested
Mar 26, 2013
Results first posted
Dec 23, 2015
Last update
Nov 7, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01375764
Lead sponsor
Amgen
Responsible party
Sponsor
First posted
Jun 17, 2011
Start date
Jul 28, 2011
Primary completion
May 8, 2012
Completion
May 8, 2012
Results posted
Dec 23, 2015
Last update
Nov 7, 2022

Study contacts

MD
study director · Amgen

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Evolocumab · Ezetimibe

Start the discussion